{"name":"Grand Pharmaceutical","slug":"grand-pharma","ticker":"0512.HK","exchange":"HKEX","domain":"grandpharm.com","description":"Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series products. In addition, the company provides bio-pesticides and additives; disposal surgical products; and Chinese medicine and health food products, as well as engages in the treatment of sewage. The company has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company has a business collaboration with the Si","hq":"Wuhan, China","founded":1992,"employees":"12614","ceo":"Hou Yongtai","sector":"Specialty Pharma / Ophthalmology / Rare Disease","stockPrice":6.98,"stockChange":-0.24,"stockChangePercent":-3.32,"marketCap":"$24.4B","metrics":{"revenue":12283271168,"revenueGrowth":10.3,"grossMargin":55.2,"rdSpend":0,"netIncome":1240871040,"cash":2900569088,"dividendYield":2.34,"peRatio":11.8,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"GRN-101 patent cliff ($150.0M at risk)","drug":"GRN-101","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Grand Pharmaceutical Reports 2023 Full-Year Results","summary":"The company reported revenue growth of 15% year-over-year, driven by strong sales of its lead product, GRN-101.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"deal","headline":"Grand Pharmaceutical Partners with Biotech Firm to Develop New Rare Disease Treatment","summary":"The partnership aims to accelerate the development of a novel therapy for a rare genetic disorder.","drugName":"","sentiment":"neutral"},{"date":"2023-08-22","type":"regulatory","headline":"FDA Approves Grand Pharmaceutical's GRN-101 for Treatment of Inherited Retinal Disease","summary":"The approval marks a significant milestone for the company, which has been working to bring this treatment to patients for several years.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE1xdzdDSWlUTXFmdGlyclFnTldHenptempSUlNnUkUwX2pqX0NISjlncFh0amJxWHlXZ1hXZlVWTFFQVmhaTlZPVy1vZ0lwUlpwd2lhYnVR?oc=5","date":"2025-08-05","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Sunshine Lake Pharma Co., Ltd. (6887.HK) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Sunshine Lake Pharma Co., Ltd. (6887.HK) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxONHVpVFhGUnlRcDZEcDNFc096TkNqSGZoQlR5UlluYlduU2NVQkhJaTZCaUJpNXBfMThpaGp3WVpTRnFfcG1lZmFzM1FndzdtbFhKVHFYMk12NFFEcmlhNEFJY2ZfcXFaNlppeDl5R1VRSkMxYWMzb1RSX1prNDBGMmt3QTJpVUhReXFBS0FjdVFiU0hNc0FnNXRObTFQd1VyYktBNUxPUVZ5U2VwaGRhdTUyV0Q0ei03bzdjS0dzYzNHSC11YmkzVQ?oc=5","date":"2024-11-06","type":"trial","source":"Ophthalmology Times","summary":"Formosa Pharmaceuticals announces top-line results from Chinese trial evaluating APP13007 - Ophthalmology Times","headline":"Formosa Pharmaceuticals announces top-line results from Chinese trial evaluating APP13007","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE0tZllEWU5NN21zSmxHV2JRNVgtb3hQdnJydDFyZFpCek9WREh2U1E1RnhsMTExSUZyZG1OVncxZXI4c01PalV6M2hqUlRRNHAtTkF3eXBMVVVabnVjSDNXYlROMXN6UllGR196VF9SMVJuemhLQVktZg?oc=5","date":"2023-12-18","type":"pipeline","source":"The Standard (HK)","summary":"Eye on the prize - The Standard (HK)","headline":"Eye on the prize - The Standard (HK)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPdldZMHpGd1hVTEtsZmJDczF0SUhYQndxcXdWYWx5TGxqVUpXY0JfVjVGenNUXzEtY2JKRGJqam40bGZEY2NmdDlPeFhwdlI4cXF2X2JsXzluOWdpdTU5WFd6a3N4VFNZeEp2Vm1MNTBqZ0dLM3RnSnZrXzk0N0MwdGd6WVhwOUlHa2VGSWpER3I?oc=5","date":"2023-06-02","type":"pipeline","source":"The Standard (HK)","summary":"Brain cancer drug gets green light - The Standard (HK)","headline":"Brain cancer drug gets green light - The Standard (HK)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxOeWYxSmlXbzFZWFh5ZXVIeXN5S2pGVlJobU5BcU5ONmFmb1lIUS1MZDJKRGtGUmp6NkttUWh5TDBUSlJCRW1LRlJpQ0lpZ1Fka3ViWndLVFpDR2FOeWE3RHBoX1JqdVRPRlZhWExGUlNlQ0J5dE5LTF9nQUpQQ1RyaW12ekMtMTcwUzNIMHVIVTZNeFJnN21UdHdmalRJNGU2SU8takJ3eXRMWnZ0YTc4MFBCbW9CV1JTbUQ4Ymp1dURQX1B6SUViR2VvWjZ6Mkd5TzE4YWI3bmo?oc=5","date":"2022-02-16","type":"deal","source":"Business Wire","summary":"ITM Receives Equity Investment of EUR 25 Million from Strategic Partner Grand Pharma - Business Wire","headline":"ITM Receives Equity Investment of EUR 25 Million from Strategic Partner Grand Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE8xVFY3Wjl4bzJwSW8zeXJUM1B0NnZWdFdfTXY5YnZNYzgzTUYwZVhOOVFDR2pSdF85UzR0Q3ByVkw1Y0lrVDNONnJlclN3WWs4VnhZZVZR?oc=5","date":"2017-06-12","type":"pipeline","source":"Yahoo Finance Singapore","summary":"China Shineway Pharmaceutical Group Limited (2877.HK) stock price, news, quote and history - Yahoo Finance Singapore","headline":"China Shineway Pharmaceutical Group Limited (2877.HK) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE9wRkowSVBEcXRDU3dnVU5QRDdnV2c2WnhxamZYOG05YkVIZUZnLTMtdmdyZDhfMUdpRjZlWVVDek5jQU9IMEgxRTlkSXc0TWxqX2NsdG5n?oc=5","date":"2017-05-30","type":"pipeline","source":"Yahoo Finance Australia","summary":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK) stock price, news, quote and history - Yahoo Finance Australia","headline":"Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTFBWMWdkUkxCX3FuQWVvZzJhR1VCcFY2eGZXand6NjZhbnRJa3ZXdWdNdjhQNHJ3eXgxaVEyLVFsSjM3dEFwa0RMNVJGSlQ0dEF6blJONGN3?oc=5","date":"2017-05-25","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Consun Pharmaceutical Group Limited (1681.HK) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Consun Pharmaceutical Group Limited (1681.HK) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[{"drugName":"GRN-101","drugSlug":"generic-name-not-publicly-disclosed","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":150000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Novartis","Roche","Regeneron"],"therapeuticFocus":["Ophthalmology","Rare Diseases"],"financials":null,"yahoo":{"currentPrice":6.98,"previousClose":7.22,"fiftyTwoWeekHigh":10.2,"fiftyTwoWeekLow":5.42,"fiftyTwoWeekRange":"5.42 - 10.2","fiftyDayAverage":7.43,"twoHundredDayAverage":8.28,"beta":0.85,"enterpriseValue":27269879808,"forwardPE":10.7,"priceToBook":1.44,"priceToSales":1.99,"enterpriseToRevenue":2.22,"enterpriseToEbitda":12.27,"pegRatio":0,"ebitda":2223053056,"ebitdaMargin":18.1,"freeCashflow":0,"operatingCashflow":0,"totalDebt":4724737024,"debtToEquity":27.5,"currentRatio":1.14,"returnOnAssets":4.2,"returnOnEquity":7.4,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":3,"targetMeanPrice":11.86,"targetHighPrice":12,"targetLowPrice":11.7,"dividendRate":0.17,"payoutRatio":0.44,"fiveYearAvgDividendYield":3.17,"exDividendDate":1781222400,"insiderHeldPercent":67.6,"institutionHeldPercent":16.5,"sharesOutstanding":3501809648,"floatShares":1256064103,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":0.59,"epsForward":0.65,"revenuePerShare":3.51,"bookValue":4.86,"officers":[{"age":39,"name":"Dr. Weikun  Tang","title":"Executive Chairman"},{"age":35,"name":"Mr. Chao  Zhou","title":"CEO & Executive Director"},{"age":48,"name":"Mr. Guang  Yang","title":"Executive Director"},{"age":59,"name":"Ms. Chit Yee Lam","title":"Executive Director"},{"age":null,"name":"Liu  Hu","title":"Investor Relations Director"},{"age":56,"name":"Mr. Tin Chang  Foo CPA (Aust.), HKICPA","title":"Company Secretary"},{"age":58,"name":"Mr. Xiaofeng  Shi","title":"Chairman of Grand Pharm (China)"},{"age":null,"name":"Xiaojie  Chen","title":"Vice President"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.grandpharm.com","phone":""}}